Literature DB >> 29512729

Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells.

Wei Li1, Zhengdong Jiang1, Xue Xiao2, Zheng Wang1, Zheng Wu1, Qingyong Ma1, Lei Cao2.   

Abstract

Curcumin is a natural polyphenol compound derived from turmeric. It possesses multiple pharmacological properties, including antioxidant, anti-inflammatory and anti-tumor progression properties. Our recent study demonstrated that superoxide dismutase (SOD)-dependent production of hydrogen peroxide (H2O2) promoted the invasive and migratory activity of pancreatic cancer cells. However, whether curcumin suppresses SOD-induced cancer progression and the related mechanisms remains unclear. Since epithelial‑to-mesenchymal transition (EMT) plays a key role in tumor metastasis, the aim of the present study was to examine whether curcumin intervenes with SOD-induced EMT in pancreatic cancer and the underlying mechanism. The human pancreatic cancer cells BxPC-3 and Panc-1 were exposed to SOD in the presence or absence of curcumin, catalase (CAT, a scavenger of H2O2), or LY 294002 [a phosphoinositide-3 kinase (PI3K) inhibitor]. Intracellular reactive oxygen species (ROS) and H2O2 were evaluated by 2,7-dichlorodihydrofluorecein diacetate and H2O2 assay, respectively. The activation of p-Akt and p-nuclear factor (NF)-κB were examined by western blotting. The migratory and invasive abilities of pancreatic cancer cells were tested by the wound healing and Transwell invasion assays. The expression of E-cadherin, N-cadherin and vimentin (EMT-related genes) were measured by reverse transcription-quantitative polymerase chain reaction and western blotting at the mRNA and protein levels, respectively. The findings of the present study demonstrated that curcumin decreased SOD-induced production of ROS and H2O2 in BxPC-3 and Panc-1 cells. Curcumin was able to suppress SOD-induced invasion and migration, and it also regulated the expression of the above‑mentioned EMT-related genes and cell morphology. SOD-induced cell invasion was also inhibited by catalase and LY 294002. Furthermore, the levels of p-Akt and p-NF-κB caused by SOD could be offset by treatment with curcumin and LY 294002. To summarize, these results demonstrated that curcumin was able to prevent SOD-driven H2O2-induced pancreatic cancer metastasis by blocking the PI3K/Akt/NF-κB signaling pathway. The use of curcumin to inhibit the H2O2/Akt/NF-κB axis may be a promising therapeutic approach to the treatment of patients with pancreatic cancer.

Entities:  

Year:  2018        PMID: 29512729     DOI: 10.3892/ijo.2018.4295

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

Review 1.  Potential Mechanisms of Action of Curcumin for Cancer Prevention: Focus on Cellular Signaling Pathways and miRNAs.

Authors:  Man Wang; Shuai Jiang; Li Zhou; Fei Yu; Han Ding; Peifeng Li; Meng Zhou; Kun Wang
Journal:  Int J Biol Sci       Date:  2019-05-07       Impact factor: 6.580

2.  Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation.

Authors:  Edy Meiyanto; Herwandhani Putri; Yonika Arum Larasati; Rohmad Yudi Utomo; Riris Istighfari Jenie; Muthi Ikawati; Beni Lestari; Noriko Yoneda-Kato; Ikuko Nakamae; Masashi Kawaichi; Jun-Ya Kato
Journal:  Adv Pharm Bull       Date:  2019-08-01

Review 3.  Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition.

Authors:  Lorena Avila-Carrasco; Pedro Majano; José Antonio Sánchez-Toméro; Rafael Selgas; Manuel López-Cabrera; Abelardo Aguilera; Guadalupe González Mateo
Journal:  Front Pharmacol       Date:  2019-07-30       Impact factor: 5.810

4.  Differential Expression Profiles of the Transcriptome and miRNA Interactome in Synovial Fibroblasts of Rheumatoid Arthritis Revealed by Next Generation Sequencing.

Authors:  Chia-Chun Tseng; Ling-Yu Wu; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Po-Lin Kuo; Jeng-Hsien Yen
Journal:  Diagnostics (Basel)       Date:  2019-08-18

5.  Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.

Authors:  Meng-Dan Zhao; Jun-Qin Li; Feng-Ying Chen; Wei Dong; Li-Juan Wen; Wei-Dong Fei; Xiao Zhang; Pei-Lei Yang; Xin-Mei Zhang; Cai-Hong Zheng
Journal:  Int J Nanomedicine       Date:  2019-12-02

6.  Antitumor Effects of 10058-F4 and Curcumin in Combination Therapy for Pancreatic Cancer In Vitro and In Vivo.

Authors:  Zhang Jie; Zhang Jinna; Zhang Jingjun; Li Pengcheng; Yang Fang; Chen Qinyang; Chen Taiyu; Jiang Hequn; Ren Tao
Journal:  J Healthc Eng       Date:  2022-03-24       Impact factor: 2.682

7.  Anhydroicaritin Inhibits EMT in Breast Cancer by Enhancing GPX1 Expression: A Research Based on Sequencing Technologies and Bioinformatics Analysis.

Authors:  Feifei Li; Youyang Shi; Xiaojuan Yang; Zhanyang Luo; Guangtao Zhang; Kui Yu; Feng Li; Lixin Chen; Youkang Zhao; Ying Xie; Yuanyuan Wu; Jianfeng Yang; Xiqiu Zhou; Sheng Liu
Journal:  Front Cell Dev Biol       Date:  2022-02-01

Review 8.  Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.

Authors:  Daniel L Pouliquen; Alice Boissard; Cécile Henry; Olivier Coqueret; Catherine Guette
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

9.  Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression.

Authors:  Xinzhou Deng; Chunli Chen; Feng Wu; Li Qiu; Qing Ke; Renhuang Sun; Qiwen Duan; Ming Luo; Zhiguo Luo
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

10.  Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in tamoxifen‑resistant breast cancer cells.

Authors:  Jiaqin Cai; Hong Sun; Bin Zheng; Mumu Xie; Chenxia Xu; Guifeng Zhang; Xuhui Huang; Jie Zhuang
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.